Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Nivolumab Plus Chemotherapy for Primary Tracheal Squamous Cell Carcinoma
NCT05964101Phase 2Recruiting
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
- Start
- Oct 2023
- Primary completion
- Aug 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab in Tracheal squamous cell carcinoma (TSCC), sponsored by The First Affiliated Hospital of Guangzhou Medical University. Started Oct 2023; status: recruiting.
02
Drugs
03
Conditions
Tracheal squamous cell carcinoma (TSCC)
Beyond the preview
Go deeper on NCT05964101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05964101.